Parameter
| Biomarker | c-Myb | Full name | Cellular myeloblastosis oncogene | Molecular Type | Nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Early diagnosis、Disease progression monitoring | ||
| Disease | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine, kidney tissue ( immunohistochemistry, protein detection ) | ||
| Pathobiological Mechanisms | Regulate renal fibrosis-related pathways, and abnormal expression promotes CKD progression | ||||
| Clinical Availability Status | Research verification stage | ||||
| Notes and Dynamics | It is an early sensitive marker of adverse outcomes of chronic kidney disease such as IgA nephropathy and Henoch-Schonlein purpura nephropathy. Larger sample size is needed to verify its clinical value. | ||||